Evidence map›Paper›PMID 22179316›Full record

ArticleNature medicine2011

Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway.

Hyunkyung Jeong, Dena E Cohen, Libin Cui, Andrea Supinski, Jeffrey N Savas, Joseph R Mazzulli, John R Yates, Laura Bordone, Leonard Guarente, Dimitri Krainc

Open access · greenAbstract read
In one paragraph

Article in Nature medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 210 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
210citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

210 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. SIRT1 in Neurodegenerative Diseases: Molecular Mechanisms, Disease Relevance, and Therapeutic Potential.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Erythropoietin (EPO) Alleviates Chronic Stress-Induced Depression by Modulating SIRT1-Mediated Mitochondrial Function.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Article

150 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Hyunkyung JeongDepartment of Neurology, Massachusetts General Hospital, MassGeneral Institute for Neurodegenerative Disease, Harvard Medical School, Charlestown, Massachusetts, USA.
Dena E Cohen
Libin Cui
Andrea Supinski
Jeffrey N Savas
Joseph R Mazzulli
John R Yates
Laura Bordone
Leonard Guarente
Dimitri Krainc
Harvard University · USMassachusetts Institute of Technology · USScripps Research Institute · USMaineGeneral Medical Center · US

Funding

ZDS2P REGULATES SWE1P-DEPENDENT POLARIZED CELL GROWTH IN S CEREVISIAEP41RR011823 · NCRR · UNIVERSITY OF WASHINGTON · PI DAVIS, TRACY · 1996 to 2011
$24.7M
Quantitative Proteome Analysis of Brain DevelopmentR01MH067880 · NIMH · SCRIPPS RESEARCH INSTITUTE, THE · PI YATES III, JOHN R · 2003 to 2017
$7.1M
Transcriptional Regulation of PGC-1 in Huntington's DiseaseR01NS051303 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI KRAINC, DIMITRI · 2008 to 2011
$1.8M
NCRR NIH HHS P41 RR011823NCRR NIH HHS P41RR011823-15NIMH NIH HHS R01 MH067880NIMH NIH HHS R01MH067880-08NINDS NIH HHS R01 NS051303NINDS NIH HHS R01NS051303
6 · The paper itself

Abstract

Sirt1, a NAD-dependent protein deacetylase, has emerged as a key regulator of mammalian transcription in response to cellular metabolic status and stress. Here we show that Sirt1 has a neuroprotective role in models of Huntington's disease, an inherited neurodegenerative disorder caused by a glutamine repeat expansion in huntingtin protein (HTT). Brain-specific knockout of Sirt1 results in exacerbation of brain pathology in a mouse model of Huntington's disease, whereas overexpression of Sirt1 improves survival, neuropathology and the expression of brain-derived neurotrophic factor (BDNF) in Huntington's disease mice. We show that Sirt1 deacetylase activity directly targets neurons to mediate neuroprotection from mutant HTT. The neuroprotective effect of Sirt1 requires the presence of CREB-regulated transcription coactivator 1 (TORC1), a brain-specific modulator of CREB activity. We show that under normal conditions, Sirt1 deacetylates and activates TORC1 by promoting its dephosphorylation and its interaction with CREB. We identified BDNF as a key target of Sirt1 and TORC1 transcriptional activity in both normal and Huntington's disease neurons. Mutant HTT interferes with the TORC1-CREB interaction to repress BDNF transcription, and Sirt1 rescues this defect in vitro and in vivo. These studies suggest a key role for Sirt1 in transcriptional networks in both the normal and Huntington's disease brain and offer an opportunity for therapeutic development.

Indexed as

AnimalsBrain-Derived Neurotrophic FactorCell LineCyclic AMP Response Element-Binding ProteinDisease Models, AnimalGene Expression RegulationHumansHuntingtin ProteinHuntington DiseaseMiceMice, Inbred C57BLNerve Tissue ProteinsNeuronsNuclear ProteinsRatsSignal TransductionBrain-Derived Neurotrophic FactorCreb1 protein, mouseCrtc1 protein, mouseCyclic AMP Response Element-Binding ProteinHtt protein, mouseHuntingtin ProteinNerve Tissue ProteinsNuclear ProteinsSirt1 protein, mouseSirtuin 1Transcription Factors

Identifiers

PMID22179316
PMCPMC3509213
OpenAlexW1556756535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.